Board of Directors

Dr. Berger was appointed a member of the Arcus Board in February 2025. Dr. Berger joined Gilead Sciences, Inc. in January of 2025 as its Chief Medical Officer. In his role at Gilead, he is responsible for leading the company’s clinical development and medical affairs strategy for all of Gilead’s medicines throughout the product lifecycle. …With over 25 years of experience in preclinical and clinical drug development, Dr. Berger plays a pivotal role in advancing Gilead’s mission to deliver transformative therapies to patients worldwide. Prior to Gilead, Dr. Berger served in executive leadership positions at Sanofi, Genentech, Bayer HealthCare and Amgen. Dr. Berger is a board-certified Internist, Hematologist and Oncologist with full academic credentials and clinical experience.

Ms. Falberg has served as a member of the Arcus board since September 2017. Previously she served as EVP and CFO of Jazz Pharmaceuticals and was responsible for strategy, corporate development, corporate communications, and information technology. …Ms. Falberg is currently on the Board of Directors for The Trade Desk, Tricida and Nuvation Bio and previously served on the Board of Directors of Aimmune Therapeutics, Axovant Gene Therapies, Urogen Pharma and Medivation until its acquisition by Pfizer.

Dr. Higgins currently serves as Senior Vice President Research, Innovation & Portfolio at Gilead Sciences, Inc. She joined Gilead in 2010 and in her first nine years led Biology, leading a significant expansion of the therapeutic area scope and capabilities of the department. …

Prior to joining Gilead, Dr. Higgins previously served as the President & CEO of InteKrin Therapeutics and as Head of Research at Scios, Inc., a Johnson & Johnson company, where she provided leadership for drug discovery, preclinical development, and translational medicine. Dr. Higgins obtained her BA degree in Behavioral Physiology from Kenyon College and her PhD in Neuroscience from the University of California, San Diego School of Medicine and conducted her post-doctoral research in Molecular Genetics at the Howard Hughes Medical Institute at the University of California, Berkeley. Dr. Higgins currently serves on the Supervisory Board of Galapagos and the Board of Directors of Tizona Therapeutics.

Dr. Kaneko has served as a member of the Arcus board since May 2015. He is currently the Managing Director at Skyline Venture Partners and was previously the CFO and VP, Business Development at Tularik. Dr. Kaneko has also served as SVP and CFO of Ionis Pharmaceuticals. … He currently serves as a member of the Stanford Interdisciplinary Life Sciences Council.

Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients. …During his 17-year tenure at Amgen, Dr. Lacey oversaw Amgen’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience.

At Amgen, Dr. Lacey helped make significant advancements in the understanding of bone biology, playing a fundamental role in the discovery of osteoprotegerin (OPG) and in the understanding of the RANK/RANK ligand pathway in bone metabolism that paved the way for the development of Prolia® (denosumab) for osteoporosis and XGEVA® for cancer-­related bone diseases, which had combined annual sales of more than $2 billion. Denosumab has received a number of awards including the U.S. 2011 Prix Galien award for best new biotechnology product. Dr. Lacey also initiated the clinical studies of keratinocyte growth factor (KGF), which ultimately was approved as Kepivance® (palifermin) for chemotherapy patients with severe oral mucositis. Prior to joining Amgen, Dr. Lacey was on the faculty at Washington University Medical Center in St. Louis, Missouri, where he taught pathology residents and medical students, performed professional medical service in anatomic pathology, and pursued NIH-funded research in bone cell biology.

Dr. Lacey received his bachelor’s degree in biology and his MD degree from the University of Colorado where he served as Chief Resident of Anatomic Pathology in his final year of training. He is board certified in anatomical pathology. Dr. Lacey currently serves as a Board member for several biotech companies and acts as an esteemed advisor to a number of academic institutions, biotechnology companies, and venture capital firms.

Ms. Lambert is the Chief Operating Officer of Myriad Genetic Laboratories. Prior to her current position, she served in various roles including President and General Manager for the Oncology and Urology business units and Vice President of Dermatology. Prior to joining Myriad, …she was a genetic counselor at LabCorp. Mrs. Lambert received her bachelor’s degree in Biology and Sociology from Boston College and she earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University.

Mr. Machado has served as a member of the Arcus board since December 2019. He has more than 20 years of experience growing biopharmaceutical organizations from development through commercialization. He co-founded and served as CFO and CBO at Medivation until his retirement and served as a member of Medivation’s Board of Directors… until its acquisition by Pfizer. During his tenure, the company saw substantial growth and the commercial launch of Xtandi®. Prior to Medivation, Mr. Machado worked to expand access to national health plans in the U.S.

Johanna Mercier serves as Gilead’s Chief Commercial Officer, with responsibility for the global commercialization of all the company’s medicines throughout the product lifecycle. Under her leadership, Gilead works to ensure that patients around the world have access to the company’s transformational medicines...

Johanna joined Gilead in 2019 after 25 years at Bristol-Myers Squibb, where she served in a number of executive leadership positions, gaining broad experience across geographies and in all aspects of the commercial business. In her time there, she successfully evolved the culture and drove strong commercial execution with double-digit growth and multiple launches that changed the standard of care in melanoma and renal cancers.

Johanna holds a bachelor’s degree in biology from the University of Montreal and an MBA from Concordia University.

She currently serves on the board of directors of Neurocrine Biosciences, Inc. and the University of Southern California’s Leonard D. Schaeffer Center for Health Policy and Economics.

Dr. Perlman has been a long-time leader in the biotechnology field. Dr. Perlman served as Senior Director of Clinical Research at Genentech contributing to their early success, including playing a key role in the development, FDA approval and marketing of Nutropin® (somatropin). … He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s business development, investor relations and financing activities, culminating with Tularik’s acquisition by Amgen in 2004. Dr. Perlman’s experience also included serving as CEO of Affymax. He is currently Managing Director and Head of non-clinical Development of X-37, LLC, an artificial intelligence-enabled drug discovery company, as well as the Chief Medical Officer and Managing Director of Velocity Pharmaceutical Development. Dr. Perlman earned his M.D. and Ph.D. degrees from New York University, and carried out post-doctoral research in the laboratory of Nobel Laureate Professor Eric Kandel. He completed his post-graduate clinical training at NYU and Stanford School of Medicine.

Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research to understand how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered …T cells, and BRAF-targeted therapies. Dr. Ribas has served as principal investigator for multiple trials, including those involving pembrolizumab. Dr. Ribas is a Professor at UCLA, Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and Director of the UCLA Parker Institute for Cancer Immunotherapy Center. He also served as the President for the American Association of Cancer Research from 2020 to 2021.

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences, … focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at Amgen and Tularik, as well as scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the California Life Sciences Association.